Human metapneumovirus (HMPV) is a recently recognized causative agent of respiratory tract disease in individuals of all ages and especially young infants. HMPV remains poorly characterized and has been reported to replicate inefficiently in vitro. Complete consensus sequences were recently determined for two isolates representing the two proposed HMPV genetic subgroups (Biacchesi et al., Virology 315 (1) (2003) 1). We have developed a reverse genetic system to produce one of these isolates, CAN97-83, entirely from cDNA. We also recovered a version, rHMPV -GFP, in which the enhanced green fluorescent protein (GFP) was expressed from a transcription cassette inserted as the first gene, leaving the 41-nt leader region and first 16 nt of the N gene undisturbed. The ability to monitor GFP expression in living cells greatly facilitated the initial recovery of this slow-growing virus. In addition, the ability to express a foreign gene from an engineered transcription cassette confirmed the identification of the HMPV transcription signals and identified the F gene-end signal as being highly efficient for transcription termination. The ability to recover virus containing a foreign insert in this position indicated that the viral promoter is contained within the 3V -terminal 57 nt of the genome. Recombinant HMPV replicated in vitro as efficiently as biologically derived HMPV, whereas the kinetics and final yield of rHMPV -GFP were reduced several-fold. Conditions for trypsin treatment were investigated, providing for improved virus yields. Another version of HMPV, rHMPV+G1F23, was recovered that contained a second copy of the G gene and two extra copies of F in promoter-proximal positions in the order G1 -F2 -F3. Thus, this recombinant genome would encode 11 mRNAs rather than eight and would be 17.3 kb long, 30% longer than that of the natural virus. Nonetheless, the rHMPV+G1F23 virus replicated in vitro with an efficiency that was only modestly reduced compared to rHMPV and was essentially the same as rHMPV -GFP. Northern blot analysis showed that the increased number and promoter-proximal location of the added copies of the F and G genes resulted in a more than 6-and 14-fold increase in the expression of F and G mRNA, respectively, and sequence analysis confirmed the intactness of the added genes in recovered virus. Thus, it should be feasible to construct an HMPV vaccine virus containing extra copies of the G and F putative protective antigen genes to increase antigen expression or to provide representation of additional antigenic lineages or subgroups of HMPV. Published by Elsevier Inc.
Introduction
Human metapneumovirus (HMPV) was first recognized in 2001 in the Netherlands from infants and children experiencing acute respiratory tract disease (van den Hoogen et al., 2001) . HMPV has since been isolated in several continents and is thought to be worldwide in prevalence (Ebihara et al., 2003; Freymouth et al., 2003; Jartti et al., 2002; Maggi et al., 2003; Nissen et al., 2002; Peiris et al., 2003; Peret et al., 2002) . HMPV was shown to have a very high seroprevalence in samples taken from children and adults over a 40-year period Ebihara et al., 2003; Freymouth et al., 2003; Maggi et al., 2003; Peret et al., 2002; van den Hoogen et al., 2001) , suggesting that it is a newly recognized rather than newly emerging virus. HMPV resembles human respiratory syncytial virus (HRSV) with regard to disease signs and the ability to infect and cause disease in the young infant in particular as well as in individuals of all ages Falsey et al., 2003; Greensill et al., 2003; Maggi et al., 2003; Osterhaus and Fouchier, 2003; Peret et al., 2002; Viazov et al., 2003) . Even though the epidemiology of HMPV and its impact on human health need to be further studied and defined, it is thought to be an important agent of pediatric respiratory tract disease for which a vaccine should be developed. Live attenuated vaccines are being developed for HRSV and human parainfluenza viruses types 1, 2, and 3, and a live attenuated HMPV vaccine might be appropriate to include as part of this strategy.
HMPV is an enveloped virus with a genome that is a single negative strand of RNA of approximately 13 kb (Biacchesi et al., 2003; van den Hoogen et al., 2001 van den Hoogen et al., , 2002 . It has been classified presumptively, together with avian metapneumovirus (AMPV), in the Metapneumovirus genus, Pneumovirus subfamily, Paramyxovirus family of the Order Mononegavirales. The Pneumovirus subfamily contains a second genus, Pneumovirus, represented by HRSV. A nearly complete genome sequence was determined for the prototype Netherlands 00-1 strain of HMPV , and complete genome sequences were determined for two Canadian strains, CAN97-83 and CAN98-75, which represent the two proposed HMPV genetic subgroups (Biacchesi et al., 2003) . These studies confirmed that like AMPV, the 3Vto 5VHMPV gene order is N-P-M-F-M2-SH-G-L. The mRNA encoded by the M2 gene contains two overlapping open reading frames (ORFs) that have the potential to encode separate proteins, M2-1 and M2-2, as is the case for HRSV (Bermingham and Collins, 1999; Collins et al., 1990 Collins et al., , 1996 Jin et al., 2000) . By analogy to AMPV and HRSV, the HMPV proteins are (listed according to gene order) N, nucleocapsid RNA binding protein; P, phosphoprotein; M, matrix protein; F, fusion glycoprotein; M2-1, transcription elongation factor; M2-2, RNA synthesis regulatory factor; SH, small hydrophobic surface protein; G, major attachment protein; and L, major polymerase subunit. To date, none of these predicted HMPV proteins have been identified or characterized by direct biochemical means, and their functions remain to be confirmed. HMPV has been described as being difficult to isolate and propagate, reflecting its trypsin dependence, slow replication, and limited range of susceptible cell lines van den Hoogen et al., 2001) .
To characterize this newly recognized Pneumovirus, we have developed a reverse genetic system based on the CAN97-83 isolate (HMPV83), one of the isolates for which a complete genome consensus sequence was recently published (Biacchesi et al., 2003) . The development of this recovery system was facilitated by the expression of enhanced green fluorescent protein (GFP) from an additional gene inserted into the genome of recombinant HMPV (rHMPV), by which the recovery of this slowly growing virus was monitored. We show that rHMPV replicates in cell culture with an efficiency comparable to that of the biologically derived virus, that reasonably efficient growth can be achieved in vitro including in a cell line appropriate for vaccine manufacture, and that additional genes can be accommodated by HMPV with only a small effect on in vitro replication. This provides the basis for developing a live attenuated, multivalent HMPV vaccine.
Results
Construction of a plasmid encoding the full-length HMPV83 antigenomic RNA A cDNA clone encoding the complete 13 335-nt antigenomic RNA of HMPV isolate HMPV83 was constructed as described in Fig. 1 . Three overlapping cloned subgenomic fragments were created: fragment 1 contained the leader and the putative N, P, and M genes, bordered on the upstream end by a T7 RNA polymerase promoter (T7p) and on the downstream end by an NheI site that was created by four nucleotide substitutions in the putative M-F intergenic region as a marker to distinguish between cDNA-derived and biologically derived HMPV (Fig. 1) . Three non-viral G residues were added to the 5V end of the antigenome to enhance promoter efficiency. Fragment 2 included the putative F, M2, SH, and G genes and was bordered on the upstream side by the added NheI site and on the downstream side by a naturally occurring Acc65I site. Fragment 3 consisted of the putative L gene and trailer sequence, bordered on the upstream side by the Acc65I site and on the downstream side by part of the hepatitis delta virus ribozyme sequence ending in an RsrII site that occurs naturally within the ribozyme. The antigenomic cDNA was cloned in vector pBSKSII, which supplied the remainder of the hepatitis delta virus ribozyme followed by a terminator for T7 RNA polymerase (T7t) (Durbin et al., 1997a) . The sequence of the complete assembled cDNA was confirmed in its entirety, showing that the encoded antigenome (13 335 nt long, exclusive of non-viral nt) differed from the consensus sequence of biologically derived HMPV83 (Biacchesi et al., 2003) only by the four nt involved in the NheI marker.
Construction of pHMPV-GFP
It was anticipated that the poor growth and relative lack of empirical knowledge for HMPV would complicate the recovery and identification of the cDNA-derived virus. Therefore, the pHMPV antigenomic cDNA was modified by insertion of an additional gene encoding the enhanced green fluorescent protein (GFP). This would provide a means to monitor the recovery of rHMPV in living cells at all stages of transfection and passage. One prerequisite for the expression of a foreign ORF inserted into a mononegavirus genome is that it be flanked by appropriate GS and GE signals to direct transcription by the viral polymerase. Putative consensus sequences of the HMPV GS (GGGACAAnTnnnAATG) and GE (AGTTAATTAAAAA) motifs were determined previously from sequence alignments of noncoding sequences (Biacchesi et al., 2003; van den Hoogen et al., 2002) . The GFP ORF was inserted into the HMPV genome such that its ATG was replaced by that of the N gene. This left undisturbed the 41-nt leader region and first 16 nt of the N gene, including the N GS signal (Fig. 2) .
The placement of GFP as the first gene should provide for a high level of transcription. The downstream end of the GFP ORF was modified to be followed by the GE signal of the HMPV F gene, and was followed in turn by a 2-nt intergenic region identical to that found between the N and P genes, followed by the complete HMPV N gene. As described for Fig. 2 . Insertion of a transcription cassette encoding the green fluorescent protein (GFP) into the promoter-proximal position of HMPV. As described in the Materials and methods, two PCR fragments were constructed: Fragment A contained the GFP ORF (black rectangle) that was flanked on the upstream side by nt 12 -57 of the HMPV antigenome, including a naturally occurring MluI site, most of the leader region, and the N GS motif. The GFP ORF was designed to initiate with the ATG start codon of the N gene (underlined) and thus is preceded by the first 57 nt of the HMPV antigenome. The GFP ORF was flanked on its downstream side by an HMPV GE motif that was taken from the F gene and contains a naturally occurring PacI site. Fragment B contained on the upstream end a partial copy of a GE signal including the PacI site, followed by a 2-nt intergenic (ig) region that is identical to that of the N-P junction, followed by a copy of the N GS signal and the upstream end of the N ORF, ending at a naturally occurring AvrII site. The two fragments were cloned into the MluI -AvrII window of the pHMPV antigenome plasmid. In the sequences shown, translational initiation and termination codons are underlined, restriction sites are italicized and underlined, and GS and GE motifs are boxed. The sequence numbering refers to the complete sequence of biologically derived HMPV83 antigenome. The total length of the added GFP transcription cassette (which begins in fragment A after the nucleotide numbered 41 and ends in fragment B before the nucleotide numbered 42) was 746 nt. Fig. 1 . Construction of plasmid pHMPV83 expressing the complete antigenomic RNA of HMPV83. Three overlapping cDNA fragments (numbered 1 -3) covering the complete antigenome were generated by RT-PCR, and were assembled in pBSKSII, which contains the hepatitis delta virus ribozyme (y ribo) (Perrotta and Been, 1991) followed by a terminator for T7 RNA polymerase (T7t). This vector also contained a polylinker with AatII, NheI, and Acc65I sites, which served to accept the cloned fragments 1, 2, and 3. The complete antigenomic cDNA was designed and confirmed to be identical to the published consensus sequence of biologically derived HMPV83 (Biacchesi et al., 2003) except for 4 nt substitutions (underlined) that were introduced to create an NheI marker restriction site in the M-F intergenic region. The leader end of the antigenome cDNA was flanked by the T7 promoter (T7p), and three additional, nonviral G residues were added to the leader end to improve the efficiency of the promoter. The complete pHMPV83 plasmid contains 16 333 bp.
pHMPV, the complete sequences of the antigenomic HMPV-GFP cDNA and flanking sequences in pHMPV -GFP also were confirmed by sequence analysis. The length of the encoded rHMPV -GFP antigenome, exclusive of non-viral nt, would be 14 083 nt, 5.6% larger than the naturally occurring genome for HMPV83.
Recovery of infectious rHMPV and rHMPV -GFP
The antigenome plasmid pHMPV -GFP was transfected into BSR T7/5 cells, which stably express the T7 RNA polymerase, together with support plasmids encoding the N, P, L, and M2-1 proteins. Two days post-transfection, trypsin was added, the cells were incubated for 3 days and scraped into the medium, and the total suspension was passaged onto LLC-MK2 or Vero cells. When transfected, cells were examined by fluorescent microscopy on successive days post-transfection, green cells were visualized by day 2 that initially consisted of scattered isolated cells and subsequently formed small foci of two or more cells that later on exhibited cytopathic effect consistent with HMPV. When the transfection monolayer was passaged to fresh cells, single green cells were visualized about 24 h post-infection and developed over successive days into multicellular foci. The ability to monitor GFP expression greatly facilitated the initial recovery, which was then also readily achieved for rHMPV lacking the GFP marker.
Infectious rHMPV -GFP also was recovered when the M2-1 support plasmid was omitted from the panel of support plasmids (not shown). This result alone does not necessarily indicate that M2-1 is not required for recovery, because the possibility exists that M2-1 is expressed from the antigenome plasmid, as was found in the case of RSV . Inclusion of pT7-M2-1 in the transfection had a positive effect on recovery, resulting in two-or threefold more initial recovery events per well. No infectious virus was recovered when the N, P, or L support plasmid was omitted.
The expression of GFP in cells infected with rHMPV -GFP showed that the virus was cDNA-derived and not a contaminating biologically derived HMPV. The rHMPV and rHMPV -GFP viruses were confirmed to be HMPV based on reactivity in both an immunofluorescence assay and a viral plaque immunostaining assay with rabbit antiserum that had been raised against gradient-purified, biologically derived HMPV (data not shown). For rHMPV -GFP, the number of foci of GFP-expressing cells counted before fixation equaled the number of foci that were reactive after immunostaining, showing that the virus population was homogeneous and stably expressing GFP after five passages in cell culture. In addition, RT-PCR performed on virion RNA (vRNA) following three passages in vitro confirmed that both the rHMPV and rHMPV -GFP genomes were efficiently copied and amplified with HMPV-specific primers, that both contained the NheI restriction marker site whereas biologically derived HMPV did not, and that the rHMPV -GFP virus contained the expected GFP insert (not shown). The expression of the inserted GFP coding sequence also was characterized by Northern blot hybridization. Cells were infected with biologically derived HMPV83, rHMPV, rHMPV -GFP, or were mock infected, and total intracellular RNA was isolated 3 days later and analyzed by Northern blot hybridization with double-stranded DNA probes specific to the GFP or M genes. As shown in Fig. 3 , the GFP-specific probe hybridized only with RNA from rHMPV -GFP-infected cells (lane 4), and detected an abundant RNA band of the appropriate size to be the predicted 746-nt (exclusive of polyA) GFP mRNA transcribed from the inserted transcription cassette. This showed that the putative HMPV GS and GE transcription signals Fig. 3 . Northern blot analysis of GFP mRNA expressed by the rHMPV -GFP virus. LLC-MK2 cells were mock-infected (lanes 1 and 5) or infected at an MOI of 3 PFU/cell with HMPV83 (lanes 2 and 6), rHMPV (lanes 3 and 7), or rHMPV -GFP (lanes 4 and 8). Three days later, total intracellular RNA was isolated, electrophoresed on 1% agarose-formaldehyde gels, transferred to charged nylon, and analyzed by hybridization to double-stranded indeed functioned in the context of the foreign ORF to direct the synthesis of a monocistronic GFP RNA. The GFP probe also hybridized to several larger RNAs that were of low abundance and appeared to represent GFP-N, GFP-N-P, and GFP-N-P-M readthrough mRNAs, as well as to a large, faint band that was of the appropriate size to contain rHMPV -GFP genome and antigenome RNA. Analysis with the Mspecific probe identified bands of the appropriate sizes to be the predicted 853-nt monocistronic M mRNA as well as bands representing the P-M and N-P-M readthrough mRNAs. The M probe also detected the genome and antigenome RNA band for each virus, which in rHMPV -GFP would be 748 nt larger than HMPV83 or rHMPV due to the presence of the GFP transcription cassette (Fig. 3 , lanes 3, lanes 6, 7, and 8).
The rHMPV virus was compared to its biologically derived HMPV83 parent and to rHMPV -GFP with regard to the efficiency of multicycle replication in vitro in LLC-MK2 cells. As shown in Fig. 4 , rHMPV replicated with an efficiency that was similar to that of its biologically derived counterpart. This confirmed that rHMPV was fully competent for multicycle growth, indicating that the previously determined HMPV83 consensus sequence is functional and appears to encode a wild-type virus. HMPV83 and rHMPV reached peak titers 11 days after infection. In comparison, the titer of rHMPV -GFP continued to rise throughout the 13 days of the experiment. Compared to the rHMPV peak titer reached on day 11, the highest rHMPV -GFP titer obtained on day 13 was 7.5-fold reduced. The final titer of rHMPV at day 13 of the experiment was threefold higher than that of rHMPV -GFP. Thus, the insertion of a foreign insert can be accommodated by HMPV without a drastic effect on in vitro replication.
Optimized trypsin regimen to increase rHMPV -GFP growth
It was previously shown that influenza A virus replication in Vero cells was impaired by rapid inactivation of trypsin in the culture fluids, and that the repeated addition of fresh trypsin to the culture medium restored the multicycle growth pattern and high viral yields (Kaverin and Webster, 1995) . We therefore examined the effect of various conditions of trypsin treatment on the growth of rHMPV -GFP. Two different cell lines, LLC-MK2 and Vero, were infected with 0.01 PFU of rHMPV -GFP per cell and incubated at 32 jC with the following trypsin regimen: (i) no trypsin, (ii) 5 Ag/ml of trypsin added on day 0 only, 2.5 Ag/ml added on day 0 and replenished thereafter at (iii) 24 or (iv) 48 h intervals, or 5 Ag/ml added on day 0 and replenished thereafter at (v) 24 h or (vi) 48 h intervals, with the last trypsin addition on day 8 (24 h interval series) or 9 (48 h interval series). Higher levels of trypsin were not tested because of the destructive effect on the cell monolayers. The cells were photographed under fluorescent light at daily intervals up to day 9 to visualize GFP expression; some of these data are shown in Fig. 5A . The medium overlying the cells was completely removed at the time points indicated in Figs. 5B and C up to day 12, and analyzed by plaque titration.
In the absence of added trypsin, the expression of GFP could be visualized by 24 h in a small subset of cells whose numbers appeared to remain essentially constant throughout the course of the experiment (Fig. 5A) . It is not known whether the GFP-positive cells observed on, for example, day 9 were the same ones that were initially infected on day 0 or whether they represent a low cycling of cell destruction and reinfection on subsequent days. Plaque titration of the medium overlay harvested at 24 h intervals showed that the release of virus reached a maximum of over 10 3 PFU/ml on day 4 and remained at that approximate level for the remainder of the experiment (Figs. 5B, C) . Thus, apparently, a few cells produced virus over this time period that was poorly infectious for multicycle infection in the absence of trypsin but could be scored by plaque assay performed in the presence of trypsin. The results were similar for LLC-MK2 versus Vero cells, although the LLC-MK2 cells yielded somewhat higher titers of virus.
In cells that received a single dose of 5 Ag/ml of trypsin on day 0, an increase in the number of GFP-expressing cells was evident with time out to day 12 (day 9 is shown in Fig.  5A ). Somewhat surprisingly, the monolayers remained largely intact throughout the 12-day period of incubation despite the large number of infected cells. CPE consisting of scattered enlarged cells with disrupted membrane structures Fig. 4 . Comparison of the multi-step growth kinetics of biologically derived HMPV83, rHMPV, and rHMPV -GFP. LLC-MK2 cells were infected at a multiplicity of infection of 0.01 with HMPV83 (5), rHMPV (.), or rHMPV -GFP (E). Supernatants (0.5 ml out of a total medium volume of 2 ml per well) were taken on indicated days post-infection and replaced by an equivalent volume of fresh medium containing 5 Ag/ml of trypsin. The samples were flash frozen and analyzed later by plaque assay and immunostaining. Each time point was represented by two wells, and each virus titration was done in duplicate. Means are shown. The expression of GFP was monitored daily by fluorescent microscopy. Photographs are shown for 5, 7, and 9 days post-transfection for cultures that received no trypsin, 5 Ag/ml of trypsin added on day 0 only, or 5 Ag/ml of trypsin added on day 0 and replenished every 24 h. Multi-step growth curves are presented for LLC-MK2 cells (B) and Vero cells (C). Infected cells received no trypsin (n), 5 Ag/ml of trypsin added on day 0 only (E), 2.5 Ag/ml of trypsin added on day 0 and replenished, on indicated time points, every 24 h ( . ) or 48 h (Â), or 5 Ag/ml of trypsin added on day 0 and replenished, on indicated time points, every 24 h (x) or 48 h (+) (with the last trypsin addition on day 8 or 9, respectively). The complete medium overlay was harvested at indicated time points. Each time point was represented by two wells, and each virus titration was done in duplicate. The detection limit of this assay is 0.4 log 10 PFU per ml of sample. Means are shown.
was evident by day 9, which later led to detachment of the affected cells from the monolayer (not shown). The formation of multicellular foci was evident by day 3, although large syncytia were not observed. Under these conditions, the titer of released virus reached a maximum of approximately 10 5 PFU/ml on day 7 that was subsequently maintained (Figs. 5B, C) . The titers obtained with LLC-MK2 were slightly higher than those with Vero cells. It was somewhat surprising that the release of virus appeared to level off, because the number of GFP-expressing cells appeared to continue to increase; for example, compare days 7 and 9 (Fig. 5A ).
Other cells received 5 Ag/ml of trypsin on day 0 that was replenished at 24 intervals. This resulted in a faster virus spread and an increasing number of GFP-expressing cells (Fig. 5A ) and high titers of released virus (Figs. 5B, C), which in this particular experiment was 6.9 Â 10 6 PFU/ml with LLC-MK2 cells compared with 6.2 Â 10 6 for Vero cells. Similar results were obtained when 2.5 Ag of trypsin were used instead of 5 Ag. Spread of infection through the Vero cell monolayers was faster as compared with virus spread observed in LLC-MK2 cells. Interestingly, Vero cells consistently produced a greater number of GFP-expressing cells compared to LLC-MK2, but a slightly lower titer of released virus. Small syncytia as shown in Fig. 5A on day 9 were rarely formed in LLC-MK2 cells, but were absent in Vero cells. Both Vero and LLC-MK2 cell monolayers remained largely intact until the experiment was terminated at 12 days. Because of its practical relevance, we also tested the effect of adding 2.5 or 5 Ag/ ml of trypsin on day 0 with replenishment at 48 h intervals. This resulted in a small (about twofold) drop in final titer in Vero cells, consistent with the greater need for trypsin replenishment noted previously for Vero cells (Kaverin and Webster, 1995) , but did not affect the yield in LLC-MK2 cells. 
Insertion of multiple extra genes into rHMPV
The insertion of the GFP transcription cassette into rHMPV reduced virus growth only slightly, as described above. It was of interest to investigate the effect of adding multiple, larger extra genes. We therefore replaced the GFP cassette of rHMPV -GFP with a transcription cassette containing a copy of the HMPV G ORF and, in addition, added two copies in tandem of a transcription cassette containing the F ORF in the order G1-F2-F3 (Fig. 6 ). This resulted in the plasmid pHMPV+G1F23, whose encoded antigenome contains sequences encoding 11 mRNAs rather than the 8 of the natural genome, and would be 17 343 nt long, an increase of 30% over the natural genome of 13 335 nt. This plasmid was stable in bacteria despite the presence of two identical copies of the G ORF and three identical copies of the F ORF. Recombinant virus was readily recovered from transfections with pHMPV+G1F23, and the virus appeared to replicate with an efficiency similar to that of rHMPV -GFP.
The presence and intactness of the additional genes in the genome of recovered rHMPV+G1F23 were investigated by RT-PCR performed on total RNA from recovered virus following three passages in Vero cells. RT-PCR was performed with a forward primer hybridizing to the HMPV leader region and a reverse primer hybridizing to N sequence, which yielded a single, major band of approximately 4.1 kb, the appropriate size to contain the tandem G1F2F3 supernumerary genes (not shown). The sequence of the supernumerary G1F2F3 genes could not be determined directly by RT-PCR consensus sequencing of viral RNA because primers specific to G or F would prime on each of the two copies of G and three copies of F, precluding analysis of each gene individually. Therefore, we first amplified the supernumerary genes by RT-PCR in three separate, overlapping segments. The first RT-PCR segment used a forward (positive-sense) primer (which also served as the RT primer) from the leader region and a reverse primer from the F gene (840 nt downstream of the F gene start signal): although this latter primer would prime on each copy of F, priming from the promoter-proximal copy (F2, numbered as in rHMPV+G1F23) would be the most efficient in combination with this forward primer, and yielded a f1.6 kb fragment that contained the leader, the G1 gene, and about 840 bp of the F2 gene, and was purified by gel electrophoresis for sequence analysis. The second segment was amplified by RT-PCR with an RT/forward primer located about 670 nt downstream of the F gene start, and a reverse primer located 554 nt downstream of the F gene start: although the forward primer would prime in all three copies of F and the reverse primer in all three copies of F, priming in F2 and F3 would be the only combination to result in successful amplification of a PCR fragment (f1.5 kb) that contained the downstream 978 bp part of the F2 gene, and a 554 bp upstream part of F3, and was purified by gel electrophoresis for sequence analysis. The third fragment was generated with an RT/forward primer Fig. 6 . Insertion of three additional transcription cassettes into rHMPV. The G ORF was modified by PCR to be flanked on the upstream side by nt 12 -41 of the leader region including a naturally occurring MluI site, and a copy of the G GS signal, and on the downstream side by a copy of the F GE signal including a PacI site. The F ORF was modified by PCR to be flanked on the upstream side by a partial GE signal, including a PacI site, an intergenic dinucleotide (GT) identical to that normally found between the N and P genes, and a copy of the N GS signal. On the downstream side, the F ORF was flanked by a copy of the F GE signal including a PacI site. One copy of the MluI -PacI G transcription cassette and two copies of the PacI -PacI F transcription cassette were cloned into the MluI -PacI window of pHMPV -GFP in the order G-F-F, replacing the GFP transcription cassette. In the sequences shown, translation initiation and stop signals are underlined, restriction sites are italicized and underlined, and GS and GE signals are boxed. The total length of the additional sequence was 4008 nt.
from the upstream end of F (14 nt downstream the F gene start signal) and a reverse primer from the upstream end of N: the forward primer would prime in all three copies of F, but priming in F3 would be the most efficient and would yield a f1.75 kb product that contained most of the F3 gene, and 120 bp of the N gene, and was purified by gel electrophoresis for sequence analysis. This provided an RT-PCR consensus sequence of the G1F2F3 supernumerary genes that was free of mutations, and all GS/GE signals and intergenic sequences were correct, indicating that these added genes were stably recovered in recombinant virus. To determine the effect of the gene additions on viral gene expression, cells were mock-infected or infected with biologically derived HMPV83, rHMPV, or rHMPV+ G1F23, and total intracellular RNA was isolated 3 days later and subjected to Northern blot analysis with doublestranded probes to the F, G, or M genes (Fig. 7) . The F probe detected a major band of the appropriate size to be the 1644-nt F mRNA, as well as a fainter band of genome and antigenome, which in rHMPV+G1F23 would be 4008 nt larger compared with HMPV83 or rHMPV due to the presence of the three added gene copies (Fig. 7, lane 4) . There were only trace amounts of readthrough mRNAs detected with the F probe. Phosphorimager analysis indicated that the amount of genome and antigenome for rHPMV+G1F23 compared to with HMPV83 and rHMPV was 0.9 and 0.5, respectively (corrected for the two extra copies of the F gene present in rHMPV+G1F23). In comparison, the relative amount of F mRNA for rHMPV+G1F23 compared to HMPV83 and rHMPV was six in each case. Normalized to the respective value of genome and antigenome, this corresponded to a 6.6-to 12-fold higher level of F mRNA for rHMPV+G1F23 compared with HMPV83 and rHMPV.
Northern blot analysis with the G probe detected, for each of the three viruses, a band of the appropriate size to be the 711-nt G mRNA as well as bands corresponding to SH-G and M2-SH-G readthrough mRNAs and a band corresponding to antigenome and genome RNAs (Fig. 7,  lanes 7, lanes 6, 7, and 8) . Phosphorimager analysis indicated that the amount of genome and antigenome for rHMPV+G1F23 compared with HMPV83 and rHMPV was 1.0 and 0.5, respectively (corrected for the extra copy Fig. 7 . Northern blot analysis of mRNAs expressed by rHMPV+G1F23. LLC-MK2 cells were mock-infected (lanes 1, 5, and 9) or infected at an MOI of 3 PFU/cell with HMPV83 (lanes 2, 6, and 10), rHMPV (lanes 3, 7 and 11), or rHMPV+G1F23 (lanes 4, 8, and 12). Three days later, total intracellular RNA was isolated, electrophoresed on 1% agarose-formaldehyde gels, transferred to charged nylon, and analyzed by hybridization to double-stranded 32 P-labeled DNA probe specific to the F (lanes 1 -4), G (lanes 5 -8), or M (lanes 9 -12) gene. The identities and calculated sizes of individual RNA species are indicated. of the G gene present in rHMPV+G1F23), values very similar to that observed with the F probe noted above. In comparison, the relative amount of G mRNA for rHMPV -G1F23 compared with HMPV83 and rHMPV was 14-fold and 15-fold, respectively. This would correspond to a 14-to 30-fold higher level of G mRNA for rHMPV+G1F23 compared with HMPV83 and rHMPV.
The rHMPV+G1F23 virus was compared to rHMPV and rHMPV -GFP with regard to the efficiency of multicycle replication in vitro. LLC-MK2 cells were inoculated with 0.01 PFU/cell and were incubated and sampled in the same manner as for the experiment in Fig. 4 . As shown in Fig. 8,  rHMPV+G1F23 replicated with an efficiency that was moderately reduced compared with rHMPV but was slightly higher than rHMPV -GFP. Thus, although HMPV is a rather slow-growing virus, it readily accommodates sequence modifications and additions, which opens possibilities for its future use as a vector for mucosal immunization.
Discussion
In this study, we describe the recovery of infectious HMPV from cDNA. HMPV was first recognized in 2001, and the available reports unanimously indicated that it was difficult to isolate and grow in cell culture due to its slow replication, trypsin dependence, small range of susceptible cell lines, and slow development of virus-induced CPE as a marker of virus growth. Therefore, we first constructed a recombinant virus containing an additional transcription cassette encoding GFP, inserted as first promoter-proximal gene. The ability to directly visualize virus spread in living cells compensated technically for the slow development of CPE, and the rHMPV -GFP virus proved to be very helpful both during the establishment of the HMPV reverse genetics system and in optimizing conditions for HMPV replication in vitro. In the future, rHMPV -GFP will also be useful to facilitate diagnostic tests, such as neutralization assays, because this recombinant can be visualized directly. Moreover, rHMPV -GFP will be used to study HMPV tropism and pathogenesis in animal models.
We subsequently recovered rHMPV that differed from the biologically derived virus only by the insertion of an NheI marker site. This virus replicated in vitro as efficiently as biologically derived HMPV, indicating that it will be appropriate as a starting point to develop a live attenuated HMPV vaccine. The recovery of wild-type-like rHMPV from cloned cDNA provided the first identification of functional sequences for the HMPV genome and its encoded macromolecules. Although the recovery of infectious virus from cloned cDNA has been achieved for several mononegaviruses, HMPV has the distinction of being a recently recognized, poorly characterized agent of human disease, and the development of functional sequences and a reverse genetics system is an important step for molecular epidemiology and vaccine development.
Replenishment of the trypsin in infected cell cultures yielded virus titers that increased over 10 -12 days, with a 50-to 100-fold increased final virus yield as compared with titers obtained using a single initial trypsin dose. Trypsin replenishment had a somewhat greater effect on HMPV replication in Vero cells than in LLC-MK2 cells, which is consistent with an observed rapid trypsin inactivation in Vero cell culture fluids (Kaverin and Webster, 1995) . From our ongoing experience in propagating HMPV, we have modified this protocol so that 5 Ag/ml fresh trypsin is added every second or third day without exchanging the medium. When this regimen is applied during routine production of HMPV stocks, titers of 1.0-4.0 Â 10 7 PFU/ml can be routinely achieved in monolayer cultures, which is about 1000-fold improved compared to with titers described in literature (van den Hoogen et al., 2001 ) and likely could be further improved in optimized cell fermentators. Importantly, these improved titers can be achieved in Vero cells, which are an acceptable substrate for vaccine manufacture. Conditions for efficient replication are important for virological studies in general, and are particularly important for vaccine manufacture to be feasible. These results indicate that it indeed should be feasible to develop and manufacture a live attenuated vaccine for HMPV.
The HMPV CPE that is described in the literature occurs late in infection, on average on day 17 or between day 10 and 14 (van den Hoogen et al., 2001 ). These observations are consistent with our findings, and the present results indicate that CPE lagged several days behind infection and GFP expression. This was true even when 5 Ag/ml of trypsin was added daily, indicating that the slow development of CPE did not reflect a lack of available trypsin. Although these results were obtained using rHMPV -GFP, similar results were obtained with infections involving biologically derived HMPV83 or rHMPV, in which indirect immunofluorescence assays performed on replicate HMPV-infected cells fixed at different time points after infection showed a similar situation in which most of the cells were infected days before the onset of CPE would occur (not shown). This showed that the slow onset of CPE is not due to a reduced replication or restricted spread of rHMPV -GFP.
Detection of GFP mRNA by HMPV showed that the putative N GS and F GE signals that were used to construct the transcription cassette indeed functioned to produce a monocistronic mRNA. The different Northern blot probes used in this study revealed substantial differences in the level of readthrough mRNAs associated with various HMPV genes and the GFP gene. For example, the M gene was associated with a high level of readthrough into downstream genes, whereas the GFP and F genes were associated with little readthrough. The GFP transcription cassette contained the F GE signal, suggesting that this common element is a highly efficient termination signal that is responsible for the lack of observed readthrough mRNAs.
As such, this signal should be optimal for the efficient expression of added genes.
The ability to recover infectious virus containing an insert following nt 57 relative to the 3V(leader) end of the genome indicates that HMPV, like RSV (Fearns et al., 2000; Fearns et al., 2002) , probably has a ''short'' promoter rather than the dipartite 96-nt promoter that is characteristic of Paramyxovirinae and involves a second promoter element contained within the first gene (Keller et al., 2001; Tapparel et al., 1998) . The multi-step growth of rHMPV -GFP in vitro resulted in final titers that were about threefold reduced compared with rHMPV. Because both the rHMPV and rHMPV -GFP full-length plasmids were sequenced in their entirety, and differed only in the presence of the GFP gene, the reduced in vitro growth observed for rHMPV -GFP can be attributed solely to effects from the additional gene. This might indicate that the insert effected a modest reduction in the functioning of a cis-acting element such as the promoter. Alternatively, it might be an effect of increased genome length and gene number. The genome of rHMPV -GFP is 748 nt (5.6%) longer compared with rHMPV. In addition to the difference in genome length, the presence of an additional gene as first gene in the genome might contribute to the reduced growth due to attenuation of the transcription of downstream genes.
To further explore the limits of HMPV as a vector, we designed a recombinant virus rHMPV+G1F23 that contains three additional genes in the promoter-proximal position, namely one additional copy of the HMPV G gene and two additional copies of the HMPV F gene. The rHMPV+ G1F23 virus has a total genome length that was increased compared with the wild-type virus by approximately 4 kb (30%). The production of infectious virus during multi-step growth in vitro was reduced only modestly compared with rHMPV and was equivalent to or slightly greater than that of rHMPV -GFP. This suggested that although insertion of an additional transcriptional unit into the HMPV genome resulted in a modest decrease in virus replication, this effect was not augmented further by a longer insert or a larger number of transcription cassettes within the range tested. This is offered with the caveat that virus replication might have been enhanced by the expression of the additional copies of G and F, which might have counteracted possible inhibitory effects due to genome length or gene number. Regardless of interpretation, the growth phenotype of rHMPV+G1F23 shows that the HMPV genome is quite versatile, and that the strategy described here can be used to design HMPV vaccine candidates containing additional copies of the putative antigenic determinant genes to achieve an increased gene dose for higher expression. Indeed, Northern blot analysis showed that the expression of F or G mRNA was increased more than 6-or 14-fold, respectively. The approach of adding glycoprotein genes can also be used to generate multivalent rHMPV vaccine candidates expressing antigenic determinants of HMPVs of heterologous antigenic lineages or subgroups in addition to the homologous set of genes present in the recombinant backbone.
It is generally thought that protection against respiratory disease caused by members of the Pneumovirinae can be best induced by live attenuated vaccines, particularly given the adverse effects of a previously tested formalin-inactivated HRSV vaccine (Collins and Murphy, 2002) . This is where reverse genetic systems have an essential role, as they allow the rational design of safe attenuated vaccine candidates (Collins and Murphy, 2002) . HMPV represents an important agent of pediatric respiratory tract disease for which a vaccine should be developed, which will be an important future application of the HMPV reverse genetic system.
Materials and methods

Cells and viruses
LLC-MK2 (ATCC CCL 7.1) and Vero (ATCC CCL-81) cells were maintained in OptiMEM I (Invitrogen GIBCO) supplemented with 5% fetal bovine serum. BSR T7/5 cells are baby hamster kidney 21 (BHK-21) cells that constitutively express T7 RNA polymerase (Buchholz et al., 1999) . They were maintained in Glasgow MEM supplemented with glutamine and amino acids (Invitrogen) and 10% fetal bovine serum. The Canadian HMPV isolate HMPV83 ) and the recombinant HMPVs described below were propagated in Vero, LLC-MK2, or BSR T7/5 cells in the absence of serum and the presence of 5 Ag/ml of trypsin. Virus titers were determined by plaque assay on LLC-MK2 cells under methylcellulose overlay containing 5 Ag/ml trypsin in the absence of serum, and plaques were visualized 6 days later by immunostaining with a 1:1000 dilution of a polyclonal rabbit serum raised against gradient-purified HMPV83. Growth curves were done with duplicate wells, and each aliquot was titrated in duplicate, and means were calculated.
Viral RNA isolation
Confluent monolayers of LLC-MK2 cells were infected with HMPV83 and incubated at 32 jC in the presence of 5 Ag/ml trypsin. Ten days post-infection, clarified supernatants were harvested, and virion RNA (vRNA) was isolated using the QIAamp viral RNA kit (Qiagen) according to the manufacturer's instructions.
Construction of T7 expression plasmids encoding the HMPV antigenome and N, P, M2-1, and L support proteins A complete cDNA copy of the HMPV83 genome was constructed (Fig. 1) by assembling three overlapping cDNA clones generated by RT-PCR with specific primers designed from the published HMPV83 consensus se-quence (Genbank accession number, AY297749) (Biacchesi et al., 2003) . Primer sequences are available from the authors upon request. First strand cDNA was generated from purified virion RNA using Superscript II reverse transcriptase (Invitrogen). PCR was carried out using Platinum Pfx DNA polymerase (Invitrogen). The nucleotide sequences of cloned RT-PCR fragments were determined using an ABI 3100 sequencer with the Big-Dye terminator ready reaction kit v1.1 (Applied Biosystems). Between two and six clones of each fragment were sequenced completely or in part to identify clones that contained the desired sequence free of error. ORFs encoding the putative nucleoprotein N (1185 nt), phosphoprotein P (885 nt), transcription elongation factor M2-1 (564 nt), and RNA polymerase L (6018 nt) were amplified by RT-PCR from virion RNA using specific primers whose sequences are available from the authors upon request, and were cloned into the T7 expression vector pTM1, wherein translational initiation is mediated by the internal ribosome entry site of encephalomyocarditis virus.
Construction of pHMPV -GFP
The antigenomic pHMPV83 plasmid was modified by the promoter-proximal insertion of a transcription cassette containing the ORF for enhanced GFP (Clonetech, Inc.). This cassette was assembled from two PCR fragments. The first fragment (fragment A in Fig. 2 ) contained, in 5V to 3V order relative to the antigenome, the naturally occurring MluI site at nt 12 of the leader region, followed by the remainder of the 41-nt leader region, followed by the 16-nt putative N gene-start (GS) sequence (GGGA-CAAGTGAAAATG, positive sense, HMPV83 nt 42 -57, N ORF initiation codon underlined), followed by the GFP ORF that was modified to use the ATG of the N GS signal as its initiation codon, followed by a 14-nt putative geneend (GE) sequence derived from the F gene (AGTTAAT-TAAAAAA), containing a naturally occurring PacI site (underlined). The second fragment (fragment B in Fig.  2 ) contained, in 5V to 3V order, a partial GE signal containing a PacI site, a 2-nt (GT) intergenic region identical to that of the N -P gene junction, and the N GS signal and partial N gene up to the naturally occurring AvrII site at HMPV83 nt 649. Fragments A and B were digested by MluI/PacI and PacI/AvrII, respectively, and cloned simultaneously into an intermediate construct containing cDNA fragment 1 of pHMPV83 ( Fig. 1 ) that had been digested with MluI/AvrII. This modified cDNA fragment 1 was then substituted into the AatII -NheI window of the complete pHMPV83 antigenomic cDNA clone, leading to the final construct pHMPV -GFP. The length of the encoded rHMPV -GFP antigenome, exclusive of non-viral sequence, would be 14 083 nt. The sequences of the regions that had been subjected to PCR, namely the leader, GFP, and upstream end of the N gene, were confirmed by nucleotide sequencing.
Construction of pHMPV+G1F23
cDNAs of the HMPV G or F ORF were amplified by PCR using primers that placed a G GS signal and an F GE signal at the beginning and end, respectively, of the G ORF, or an N GS signal and F GE signal at the beginning and end of the F ORF. In each case, this was followed by a GT dinucleotide intergenic region; in addition, the G transcription cassette was flanked by MluI and PacI sites, and the F cassette by PacI sites. The MluI-PacI G fragment was used to replace the MluI-PacI GFP fragment (Fig. 2) from an intermediate construct containing fragment 1 (comprising the antigenome from leader to NheI site) of pHMPV -GFP. Next, two copies of the F fragment were cloned into the PacI site of this intermediate plasmid, and restriction digestion was used to identify a clone in which the ORFs of both fragments were in the correct orientation. This G1F23-bearing intermediate fragment was combined with pHMPV fragments 2 and 3 ( Fig. 1) to yield pHMPV+G1F23. The length of the encoded rHMPV+G1F23 antigenome, exclusive of non-viral sequence, would be 17 343 nt. The sequences of the G and F cassettes were confirmed before assembly by nucleotide sequencing of intermediate clones each bearing an individual cassette.
rHMPV recovery
Confluent BSR T7/5 cells in 6-well dishes were transfected with 5 Ag of antigenomic plasmid pHMPV, pHMPV -GFP, or pHMPV+G1F23, 2 Ag each of pT7-N and pT7-P, and 1 Ag each of pT7-M2-1 and pT7-L support plasmids per well. Transfections were done with Lipofectamine 2000 (Invitrogen) in OptiMEM without trypsin or serum and maintained overnight at 32 jC. The Lipofectamine transfection medium was removed 1 day later and replaced with Glasgow MEM without trypsin or serum. Trypsin was added on day 3 to a final concentration of 5 Ag/ ml, and cell-medium mixtures were passaged onto fresh LLC-MK2 cells on day 6. The expression of GFP was monitored by fluorescent microscopy.
Northern blot analysis
LLC-MK2 cells were mock-infected or infected with HMPV83 or the indicated recombinant virus, each at an input MOI of 3 PFU/cell, incubated for 3 days, and processed to purify total intracellular RNA using an RNeasy kit (Qiagen) according to the manufacturer's instructions. RNA was electrophoresed in a 1% agarose gel in the presence of 0.44 M formaldehyde, transferred to charged nylon membrane (Hybond-N+, Amersham Biosciences), fixed by UV cross-linking, and analyzed by hybridization with denatured double-stranded 32 P-labeled DNA probes generated by random priming from GFP, M, G, or F gene cDNA fragments. Radioactivity was detected by analysis with a phosphorimager.
